Exenatide infusion decreases atrial natriuretic peptide levels by reducing cardiac filling pressures in type 2 diabetes patients with decompensated congestive heart failure

Diabetology and Metabolic Syndrome

Volumn 8, Issue 1, 2016, Pages

  Nathanson, David ^a,b   Frick, Mats ^a,b   Ullman, Bengt ^a,b   Nyström, Thomas ^a,b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM SÖDER HOSPITAL   (Sweden)

Author keywords

Atrial natriuretic peptide; Exenatide; GLP 1; Heart failure; Type 2 diabetes

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EXENDIN 4; FATTY ACID; METFORMIN; SULFONYLUREA;

ADULT; AGED; ARTERIAL PRESSURE; ARTICLE; CARDIOVASCULAR RESPONSE; CLINICAL ARTICLE; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; FATTY ACID BLOOD LEVEL; FEMALE; HEART HEMODYNAMICS; HEART OUTPUT; HEART RATE; HEART VENTRICLE PRESSURE; HUMAN; LUNG ARTERY PRESSURE; MALE; MEAN ARTERIAL PRESSURE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PULMONARY ARTERY OCCLUSION PRESSURE; RANDOMIZED CONTROLLED TRIAL; SYSTEMIC VASCULAR RESISTANCE; SYSTOLIC BLOOD PRESSURE; VERY ELDERLY;

EID: 84954119706     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/s13098-015-0116-2     Document Type: Article

References (33)

1. Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet. 2006;368(9548):1696-705. doi: 10.1016/S0140-6736(06)69705-5.
2. Nystrom T, Gonon AT, Sjoholm A, Pernow J. Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism. Regul Pept. 2005;125(1-3):173-7. doi: 10.1016/j.regpep.2004.08.024.
3. Nystrom T, Gutniak MK, Zhang Q, Zhang F, Holst JJ, Ahren B, et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab. 2004;287(6):E1209-15. doi: 10.1152/ajpendo.00237.2004.
4. Lonborg J, Vejlstrup N, Kelbaek H, Botker HE, Kim WY, Mathiasen AB, et al. Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. Eur Heart J. 2012;33(12):1491-9. doi: 10.1093/eurheartj/ehr309.
5. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation. 2004;109(8):962-5. doi: 10.1161/01.CIR.0000120505.91348.58.
6. Sokos GG, Nikolaidis LA, Mankad S, Elahi D, Shannon RP. Glucagon-like peptide-1 infusion improves left ventricular ejection fraction and functional status in patients with chronic heart failure. J Cardiac Fail. 2006;12(9):694-9. doi: 10.1016/j.cardfail.2006.08.211.
7. Robinson LE, Holt TA, Rees K, Randeva HS, O'Hare JP. Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysis. BMJ Open. 2013. doi: 10.1136/bmjopen-2012-001986.
8. Chai W, Dong Z, Wang N, Wang W, Tao L, Cao W, et al. Glucagon-like peptide 1 recruits microvasculature and increases glucose use in muscle via a nitric oxide-dependent mechanism. Diabetes. 2012;61(4):888-96. doi: 10.2337/db11-1073.
9. Selley E, Kun S, Szijarto IA, Laczy B, Kovacs T, Fulop F, et al. Exenatide induces aortic vasodilation increasing hydrogen sulphide, carbon monoxide and nitric oxide production. Cardiovasc Diabetol. 2014;13:69. doi: 10.1186/1475-2840-13-69.
10. Lovshin JA, Barnie A, DeAlmeida A, Logan A, Zinman B, Drucker DJ. Liraglutide promotes natriuresis but does not increase circulating levels of atrial natriuretic peptide in hypertensive subjects with type 2 diabetes. Diabetes Care. 2015;38(1):132-9. doi: 10.2337/dc14-1958.
11. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens. 2003;21(6):1125-35. doi: 10.1097/01.hjh.0000059046.65882.49.
12. Kim M, Platt MJ, Shibasaki T, Quaggin SE, Backx PH, Seino S, et al. GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure. Nat Med. 2013;19(5):567-75. doi: 10.1038/nm.3128.
13. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788-803. doi: 10.1161/CIRCRESAHA.114.301958.
14. Baines AD, DeBold AJ, Sonnenberg H. Natriuretic effect of atrial extract on isolated perfused rat kidney. Can J Physiol Pharmacol. 1983;61(12):1462-6.
15. Thibault G, Garcia R, Gutkowska J, Bilodeau J, Lazure C, Seidah NG, et al. The propeptide Asn1-Tyr126 is the storage form of rat atrial natriuretic factor. Biochem J. 1987;241(1):265-72.
16. Dickstein K, Aarsland T, Hall C. Plasma N-terminal atrial natriuretic factor: a predictor of survival in patients with congestive heart failure. J Cardiac Fail. 1997;3(2):83-9.
17. Dickstein K, Larsen AI, Bonarjee V, Thoresen M, Aarsland T, Hall C. Plasma proatrial natriuretic factor is predictive of clinical status in patients with congestive heart failure. Am J Cardiol. 1995;76(10):679-83.
18. Globits S, Frank H, Pacher B, Huelsmann M, Ogris E, Pacher R. Atrial natriuretic peptide release is more dependent on atrial filling volume than on filling pressure in chronic congestive heart failure. Am Heart J. 1998;135(4):592-7.
19. Li CJ, Yu Q, Yu P, Yu TL, Zhang QM, Lu S, et al. Changes in liraglutide-induced body composition are related to modifications in plasma cardiac natriuretic peptides levels in obese type 2 diabetic patients. Cardiovasc Diabetol. 2014;13:36. doi: 10.1186/1475-2840-13-36.
20. Rudovich N, Pivovarova O, Gogebakan O, Sparwasser A, Doehner W, Anker SD, et al. Effect of exogenous intravenous administrations of GLP-1 and/or GIP on circulating pro-atrial natriuretic peptide in subjects with different stages of glucose tolerance. Diabetes Care. 2015;38(1):e7-8. doi: 10.2337/dc14-1452.
21. Skov J, Holst JJ, Gotze JP, Frokiaer J, Christiansen JS. Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males. Endocr Connect. 2014;3(1):11-6. doi: 10.1530/EC-13-0087.
22. Nathanson D, Ullman B, Lofstrom U, Hedman A, Frick M, Sjoholm A, et al. Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety. Diabetologia. 2012;55(4):926-35. doi: 10.1007/s00125-011-2440-x.
23. Nystrom T. The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance. Horm Metab Res. 2008;40(9):593-606. doi: 10.1055/s-0028-1082326.
24. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation. 2004;110(8):955-61. doi: 10.1161/01.CIR.0000139339.85840.DD.
25. Rubattu S, Calvieri C, Pagliaro B, Volpe M. Atrial natriuretic peptide and regulation of vascular function in hypertension and heart failure: implications for novel therapeutic strategies. J Hypertens. 2013;31(6):1061-72. doi: 10.1097/HJH.0b013e32835ed5eb.
26. Berglund H, Bevegard S, Carlens P, Hedner J, Hedner T. Atrial natriuretic peptide during acute treatment of congestive heart failure. Clin Physiol. 1988;8(2):155-62.
27. Hensen J, Abraham WT, Lesnefsky EJ, Levenson B, Groves BM, Schroder K, et al. Atrial natriuretic peptide kinetic studies in patients with cardiac dysfunction. Kidney Int. 1992;41(5):1333-9.
28. Poulos JE, Gower WR Jr, Sullebarger JT, Fontanet HL, Vesely DL. Congestive heart failure: increased cardiac and extracardiac atrial natriuretic peptide gene expression. Cardiovasc Res. 1996;32(5):909-19.
29. Abassi Z, Karram T, Ellaham S, Winaver J, Hoffman A. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance. Pharmacol Ther. 2004;102(3):223-41. doi: 10.1016/j.pharmthera.2004.04.004.
30. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet. 2003;362(9380):316-22. doi: 10.1016/S0140-6736(03)13976-1.
31. Wu AH, Harrison A, Maisel AS. Reduced readmission rate for alternating diagnoses of heart failure and pulmonary disease after implementation of B-type natriuretic peptide testing. Eur J Heart Fail. 2004;6(3):309-12. doi: 10.1016/j.ejheart.2003.12.014.
32. Davidson NC, Struthers AD. Brain natriuretic peptide. J Hypertens. 1994;12(4):329-36.
33. Sengenes C, Zakaroff-Girard A, Moulin A, Berlan M, Bouloumie A, Lafontan M, et al. Natriuretic peptide-dependent lipolysis in fat cells is a primate specificity. Am J Physiol Regul Integr Comp Physiol. 2002;283(1):R257-65. doi: 10.1152/ajpregu.00453.2001.